Sexual Dysfunction

Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.

Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.

A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

Discover groundbreaking insights in urology as Larry Lipshultz, MD, shares innovative research and strategies for male fertility challenges.

Kathrins discusses the intricacies of leading a clinical trial and why "negative" trials are important to informing care strategies.

New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.

Andrew Sun, MD, joins Pearls & Perspectives to discuss innovative approaches to testosterone therapy for enhanced health outcomes.

A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

“In 5200 men, very clearly, definitively, irrefutably, it has been shown that testosterone therapy is not associated with MACE over the course of the 12 to 24 months after commencement of testosterone therapy," says John P. Mulhall, MD.

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.

"I think that testosterone is really a medication that can be life changing for so many men, says Helen L. Bernie, DO, MPH.

"I'm so excited about them finally removing this boxed warning," says Helen L. Bernie, DO, MPH.

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors.

As the year comes to a close, we revisit some of this year’s top video content from Urology Times.

"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.

"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.

"What's important here is that there's an increased public interest in this vaginal estrogen therapy," says Elia Abou Chawareb, MD.

"We wanted to see if medical recommendations for vaginal estrogen for postmenopausal women for symptom correction have a correlation with rising interest [among patients]," says Elia Abou Chawareb, MD.

"We wanted to explore the outcomes, the compliance rates, [and] the complications with regards to Xiaflex," says Muhammed A. Moukhtar Hammad, MBBCh.

"DTC companies, especially in the men's health space, have really done a wonderful job of destigmatizing conversations," says Justin Dubin, MD.

"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.